The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Mallinckrodt Settles U.S. Opioid Drug Probe for $35 million

Mallinckrodt Settles U.S. Opioid Drug Probe for $35 million

July 12, 2017 • By Nate Raymond

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Mallinckrodt Plc., one of the largest manufacturers of the generic opioid painkiller oxycodone, will pay $35 million to resolve allegations that it failed to report suspicious drug orders, the U.S. Justice Department said on Tuesday.

You Might Also Like
  • CVS to Pay $5 Million to Resolve U.S. Drug Probe
  • New Jersey Sues Insys as Opioid Maker Settles with Massachusetts
  • U.S. to File ‘Statement of Interest’ in Lawsuits Against Opioid Makers, Distributors
Also By This Author
  • Former Insys CEO Pleads Guilty to Opioid Kickback Scheme

The deal, in which Mallinckrodt did not admit wrongdoing, marked a record settlement of claims that a drugmaker failed to properly notify the U.S. Drug Enforcement Administration of suspicious orders for drugs such as oxycodone, the Justice Department said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

U.S. Attorney General Jeff Sessions said the settlement will send a message to other drugmakers that the Justice Department will seek to hold them accountable for their actions amid a national opioid addiction epidemic.

“Mallinckrodt’s actions and omissions formed a link in the chain of supply that resulted in millions of oxycodone pills being sold on the street,” he said in a statement.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“I believe that will prevent drug abuse, prevent new addictions from starting and ultimately save lives.”

Mallinckrodt previously announced an agreement-in-principle to resolve the investigations in April. The company said it continues to deny the allegations.

Michael-Bryant Hicks, Mallinckrodt’s general counsel, said the company chose to settle “to eliminate the uncertainty, distraction and expense of litigation and to allow the company to focus on meeting the important needs of its patients and customers.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Opioids, including prescription painkillers and heroin, killed more than 33,000 people in the United States in 2015, more than any year on record, according to the U.S. Centers for Disease Control and Prevention.

According to the Justice Department, from 2008 to 2011, Mallinckrodt supplied distributors increasingly excessive amounts of oxycodone pills without notifying the DEA of the suspicious orders.

Those distributors in turn supplied the drugs to various U.S. pharmacies and pain clinics, the Justice Department said.

In addition to the monetary penalty, Mallinckrodt agreed to analyze data on orders from customers down the supply chain to identify suspicious sales, the Justice Department said.

 

Filed Under: Legal, Pharma Co. News Tagged With: Mallinckrodt Plc, national opioid addiction epidemic, opioid crisis, opioid drug probe, Oxycodone, settlement, suspicious orders

You Might Also Like:
  • CVS to Pay $5 Million to Resolve U.S. Drug Probe
  • New Jersey Sues Insys as Opioid Maker Settles with Massachusetts
  • U.S. to File ‘Statement of Interest’ in Lawsuits Against Opioid Makers, Distributors
  • U.S. Senator Expands Opioid Probe to Distributors, Drugmakers

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)